Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | HBI-2376 |
Synonyms | |
Therapy Description |
HBI-2376 inhibits SHP2, potentially leading to decreased tumor cell proliferation and inhibition of tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr 1041). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
HBI-2376 | HBI 2376|HBI2376 | SHP2 Inhibitor 20 | HBI-2376 inhibits SHP2, potentially leading to decreased tumor cell proliferation and inhibition of tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr 1041). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05163028 | Phase I | HBI-2376 | A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations | Recruiting | USA | 1 |